Oxford

The trials here

What the 14 trials at this site are about, from their registry records.

Conditions

• Chronic myeloid leukaemia5 trials
• Colorectal cancer2 trials
• Multiple sclerosis2 trials
• Acute lymphoblastic leukaemia1 trial
• Alzheimer disease1 trial
• Childhood cancers1 trial
• Huntington's disease1 trial
• Immune thrombocytopenia (ITP)1 trial
• Myeloproliferative neoplasms1 trial
• Prostate cancer1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 37 trials
• Phase 24 trials
• Phase 42 trials
• Phase 11 trial

Status

• Active, not recruiting6 trials
• Completed3 trials
• Recruiting3 trials
• Terminated2 trials

Lead sponsor

• Novartis Pharmaceuticals14 trials

Running trials

• Recruiting

  A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

  NCT07326709· Phase 3· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease

  NCT07094516· Phase 2· Novartis Pharmaceuticals· Source

• Recruiting

  Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

  NCT06855277· Phase 3· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis

  NCT06444113· Phase 4· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.

  NCT05838768· Phase 1· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids

  NCT05653219· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  Asciminib Roll-over Study

  NCT04877522· Phase 4· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

  NCT04971226· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

  NCT03650114· Phase 3· Novartis Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Acute lymphoblastic leukaemia1 recruiting
• Childhood cancers1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Huntington's disease1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Prostate cancer1 recruiting

Closed trials

• Terminated

  Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC

  NCT04952753· Phase 2· Novartis Pharmaceuticals· Source

• Terminated

  Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss

  NCT04251533· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.

  NCT03578367· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs

  NCT03106779· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients

  NCT01784068· Phase 2· Novartis Pharmaceuticals· Source